William Blau, MD
Cardiovascular Disease · Great Neck, NYNPI 1326084757
Payments from drug & device makers
Across 158 payments — averaging $19.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$558
- Amgen$454
- Sanofi-aventis U.S. LLC$299
- Amarin Pharma, Inc.$295
- AstraZeneca$206
- Boehringer Ingelheim$166
- plus $1K from 19 others
What the payments were for
- Food & beverage$2,92997%
- Education$943%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 20 | $558 |
| Amgen | 31 | $454 |
| Sanofi-aventis U.S. LLC | 15 | $299 |
| Amarin Pharma, Inc. | 15 | $295 |
| AstraZeneca | 14 | $206 |
| Boehringer Ingelheim | 9 | $166 |
| Astellas Pharma US Inc | 7 | $157 |
| Regeneron Healthcare Solutions, Inc. | 8 | $148 |
| Heartflow, Inc. | 1 | $131 |
| Merck | 7 | $128 |
| Kowa Pharmaceuticals America, Inc. | 6 | $82 |
| Edwards Lifesciences | 3 | $69 |
| Pfizer | 5 | $68 |
| GSK | 2 | $41 |
| E.r. Squibb & Sons, L.L.C. | 3 | $35 |
| Boston Scientific | 2 | $28 |
| Novartis | 2 | $28 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $22 |
| Aegerion Pharmaceuticals, Inc. | 1 | $17 |
| Biogen | 1 | $16 |
| Novo Nordisk | 1 | $15 |
| Promius Pharma LLC | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| AbbVie | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,023 in reported general payments places this provider in the 60th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 372 | $344,844 |
| Repatha SureclickEvolocumab | 262 | $219,246 |
| JardianceEmpagliflozin | 195 | $212,093 |
| XareltoRivaroxaban | 183 | $174,375 |
| EntrestoSacubitril/Valsartan | 158 | $166,225 |
| OzempicSemaglutide | 121 | $155,471 |
| FarxigaDapagliflozin Propanediol | 101 | $97,060 |
| Praluent PenAlirocumab | 152 | $91,239 |
| MounjaroTirzepatide | 79 | $83,417 |
| Repatha PushtronexEvolocumab | 76 | $56,537 |
| MultaqDronedarone Hcl | 45 | $52,797 |
| VascepaIcosapent Ethyl | 93 | $47,947 |
| JanuviaSitagliptin Phosphate | 39 | $45,044 |
| Ezetimibe | 1,195 | $27,117 |
| Rosuvastatin Calcium | 1,412 | $20,830 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $68 | $344,844372 claims |
| Boehringer IngelheimJardiance, Tradjenta | $166 | $232,731215 claims |
| Johnson & JohnsonXarelto | $558 | $174,375183 claims |
| Novo NordiskOzempic, Rybelsus | $15 | $172,099133 claims |
| NovartisEntresto | $28 | $166,225158 claims |
| AstraZenecaFarxiga | $206 | $97,060101 claims |
| MerckJanuvia, Janumet | $128 | $61,38154 claims |
| Sanofi-aventis U.S. LLCMultaq | $299 | $52,79745 claims |
| AbbVieSynthroid, Linzess | $12 | $23,211180 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $82 | $18,73927 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi | $13 | $10,09023 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in Great Neck
- James MinNew York$41.1M
- Robert RosensonNew York$6.9M
- Roxana MehranNew York$6.4M
- Roger HajjarNew York$5.2M
- Philippe GenereuxNew York$4.4M
- Vijay IyerAmherst$4.3M
- Gregg StoneNew York$3.7M
- Szilard VorosStony Brook$3.7M
- Valentin FusterNew York$2.9M
- Sean DonahoeRiverhead$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.